By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm IMDx reported on Thursday that it has entered into an agreement with Abbott to design, develop, and manufacture assays using Abbott's FDA-approved m2000 platform.

Privately held IMDx will also bring the assays through the regulatory process.

Financial and other terms of the multi-year deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.